Azithromycin in Pseudomonas aeruginosa Biofilms: Bactericidal Activity and Selection of nfxB Mutants
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Azithromycin (AZM) has shown promising results in the treatment of Pseudomonas aeruginosa chronic lung infections such as those occurring in cystic fibrosis (CF) patients. We evaluated the effect of hypermutation and alginate hyperproduction on the bactericidal activity and resistance development to AZM in P. aeruginosa biofilms. Strains PAO1, its mucA mutant (PAOMA), and their respective mutS -deficient hypermutable derivatives (PAOMS and PAOMSA) were used. Biofilms were incubated with several AZM concentrations for 1, 2, 4, or 7 days, and the numbers of viable cells were determined. During the first 2 days, AZM showed bactericidal activity for all the strains, but in extended AZM incubation for strain PAOMS and especially strain PAOMSA, a marked increased in the number of viable cells was observed, particularly at 4 μg/ml. Biofilms formed by the lineages recovered from the 7-day experiments showed enhanced AZM resistance. Furthermore, most of the independent lineages studied, including those obtained from biofilms treated with AZM concentrations as low as 0.5 μg/ml, showed MexCD-OprJ hyperexpression and mutations in nfxB . The role of nfxB mutation in AZM resistance was further confirmed through the characterization of nfxB and mexD knockout mutants. Results from this work show that, although AZM exhibits bactericidal activity against P. aeruginosa biofilms, resistant mutants are readily selected and that, furthermore, they frequently show cross-resistance to other unrelated antipseudomonal agents such as ciprofloxacin or cefepime but hypersusceptibility to others such as imipenem or tobramycin. Therefore, these results should help guide the selection of appropriate antipseudomonal therapies in CF patients under AZM maintenance treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hyperexpression of MexCD-OprJ, showed cross-resistance to other unrelated antipseudomonal agents as ciprofloxacin or cefepime but hypersusceptibility to others such as imipenem or tobramycin [95].”
From Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms (2023) · cites this paper as [95]
In the citing paper
“marked selection of resistant mutants was demonstrated to be linked to hyperproduction of the multidrug efflux pump MexCD-OprJ, associated with inactivation mutations in its negative regulator nfxB [95].”
From Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms (2023) · cites this paper as [95]
In the citing paper
“Mutation-driven resistance has been shown to be relevant also for antibiotics showing potent activity against P. aeruginosa biofilms, but not against planktonically growing cells, such as azithromycin (AZM).”
From Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms (2023) · cites this paper as [95]
In the citing paper
“The emergence of such resistant mutants was dramatically enhanced in biofilms formed by hypermutable strains [95].”
From Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms (2023) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R., D’Argenio, D. A., Miller, S. I., Ramsey, B. W., Speert, D. P., Moskowitz, S. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602138103 · Cited by 1,319
Research works printed but not linked: 45
- Bullock, W. O., J. M. Fernández, and J. M. Short. 1987. XL1 Blue: a high efficiency plasmid transforming recA Escherichia coli strain with β-galactosidase selection. BioTechniques5:376-378.
- 10.1128/AAC.49.6.2276-2282.2005 · DOI · Paper page
- 10.1126/science.284.5418.1318 · DOI · Paper page
- 10.1016/S0140-6736(02)11081-6 · DOI · Paper page
- 10.1128/JCM.42.12.5842-5845.2004 · DOI
- 10.1128/AAC.49.9.3858-3867.2005 · DOI · Paper page
- 10.1128/mr.60.3.539-574.1996 · doi:10.1128/mr.60.3.539-574.1996 · Paper page
- 10.1128/AAC.48.9.3573-3575.2004 · DOI · Paper page
- 10.1128/AAC.42.4.974 · DOI · Paper page
- 10.1128/AAC.00148-07 · DOI · Paper page
- 10.1016/S0924-8579(03)00009-8 · DOI
- 10.1128/AAC.31.4.582 · DOI · Paper page
- 10.1128/AAC.01011-06 · DOI · Paper page
- 10.1016/S1286-4579(00)01349-6 · DOI · Paper page
- 10.1159/000239440 · DOI · Paper page
- 10.1128/AAC.49.4.1377-1380.2005 · DOI
- 10.1128/AAC.36.11.2562 · DOI · Paper page
- 10.1128/AAC.44.3.710-712.2000 · DOI · Paper page
- 10.1128/AAC.01107-07 · DOI · Paper page
- 10.1128/AAC.00613-07 · DOI · Paper page
- 10.1128/JB.183.18.5213-5222.2001 · DOI · Paper page
- 10.1128/JB.187.4.1384-1391.2005 · DOI · Paper page
- 10.1128/AAC.49.8.3382-3386.2005 · DOI · Paper page
- 10.1128/AAC.50.3.975-983.2006 · DOI
- 10.2144/02335rr01 · DOI · Paper page
- 10.1128/AAC.40.4.909 · doi:10.1128/aac.40.4.909
- 10.1128/JB.00120-07 · DOI
- 10.1128/JCM.42.5.1915-1922.2004 · DOI · Paper page
- 10.1128/AAC.50.5.1680-1688.2006 · DOI · Paper page
- Oh, H., S. Stenhoff, S. Jalal, and B. Wretlind. 2003. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb. Drug Res.8:323-328.
- 10.1046/j.1365-2958.2002.02855.x · DOI · Paper page
- 10.1126/science.288.5469.1251 · DOI · Paper page
- 10.1128/AAC.48.11.4226-4233.2004 · DOI
- Oliver, A. M., and D. M. Weir. 1985. The effect of Pseudomonas aeruginosa alginate on rat alveolar macrophage phagocytosis and bacterial opsonization. Clin. Exp. Immunol.59:190-196.
- 10.1128/IAI.67.9.4744-4750.1999 · DOI
- 10.1128/iai.58.10.3363-3368.1990 · DOI · Paper page
- 10.1128/AAC.00174-07 · DOI
- 10.2144/05381ST01 · DOI
- 10.1038/nbt1183-784 · DOI · Paper page
- 10.1016/0891-5849(89)90078-6 · DOI · Paper page
- 10.1093/nar/17.24.10509 · DOI · Paper page
- 10.1038/35023079 · DOI · Paper page
- 10.1128/AAC.45.6.1930-1933.2001 · DOI
- 10.1007/s101560050042 · doi:10.1007/s101560050042
- 10.1136/thorax.57.3.212 · DOI · Paper page
Cited by
Antibiotic treatment of biofilm infections
Ciofu, O., Rojo‐Molinero, E., Macià, M. D., & Oliver, A. (2017) · APMIS · doi:10.1111/apm.12673 · Cited by 496
Self-citationMechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms
Fernández-Billón, M., Llambías-Cabot, A. E., Jordana-Lluch, E., Oliver, A., & Macià, M. D. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100129 · Cited by 170
Self-citation
Metadata
- Authors
- Mulet, X., Maciá, M. D., Mena, A., Juan, C., Pérez, J. L., & Oliver, A.
- Affiliations
- Servicio de Microbiología and Unidad de Investigación, Hospital Son Dureta, Instituto Universitario de Investigación en Ciencias de la Salud, Palma de Mallorca, Spain
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-04
- Volume
- 53
- Issue
- 4
- Pages
- 1552-1560
- ISSN
- 0066-4804
- 1098-6596
- Cited by
- 71
- References
- 1
- Language
- en
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.